Zymeworks Yönetim

Yönetim kriter kontrolleri 2/4

Zymeworks CEO'su Ken Galbraith, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 3.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.5% maaş ve 81.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.035% ine doğrudan sahiptir ve bu hisseler $ 325.07K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 1.6 yıldır.

Anahtar bilgiler

Ken Galbraith

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi18.5%
CEO görev süresi2.8yrs
CEO sahipliği0.03%
Yönetim ortalama görev süresi1.8yrs
Yönetim Kurulu ortalama görev süresi1.6yrs

Son yönetim güncellemeleri

Recent updates

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Nov 08
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 04

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

CEO Tazminat Analizi

Ken Galbraith'un ücretlendirmesi Zymeworks'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$114m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$625k

-US$119m

Sep 30 2023n/an/a

US$205m

Jun 30 2023n/an/a

US$186m

Mar 31 2023n/an/a

US$173m

Dec 31 2022US$7mUS$582k

US$124m

Sep 30 2022n/an/a

-US$224m

Jun 30 2022n/an/a

-US$237m

Mar 31 2022n/an/a

-US$240m

Dec 31 2021n/an/a

-US$212m

Sep 30 2021n/an/a

-US$211m

Jun 30 2021n/an/a

-US$223m

Mar 31 2021n/an/a

-US$194m

Dec 31 2020n/an/a

-US$181m

Sep 30 2020n/an/a

-US$215m

Jun 30 2020n/an/a

-US$173m

Mar 31 2020n/an/a

-US$163m

Dec 31 2019US$167kn/a

-US$145m

Tazminat ve Piyasa: Ken 'ın toplam tazminatı ($USD 3.37M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.19M ).

Tazminat ve Kazançlar: Ken 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Ken Galbraith (61 yo)

2.8yrs

Görev süresi

US$3,374,876

Tazminat

Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Kenneth Galbraith
Chairman of the Board2.8yrsUS$3.37m0.035%
$ 325.1k
Paul Moore
Chief Scientific Officer2.3yrsUS$1.68m0.011%
$ 100.8k
Leone Patterson
Executive VP and Chief Business & Financial Officerless than a yearVeri yokVeri yok
Mark Hollywood
Executive VP and Head of Technical & Manufacturing Operationsno dataVeri yokVeri yok
Shrinal Inamdar
Director of Investor Relationsno dataVeri yokVeri yok
Daniel Dex
Senior VPno dataVeri yokVeri yok
Diana Papove
Senior Manager of Corporate Communicationsno dataVeri yokVeri yok
Lindsey Foulkes
Vice President of Corporate Developmentno dataVeri yokVeri yok
Laura O'Connor
Vice President of Human Resources & DEI1.8yrsVeri yokVeri yok
Jeffrey Smith
Executive VP & Chief Medical Officerno dataVeri yokVeri yok
John Fann
Senior Vice President of Process Sciencesless than a yearVeri yokVeri yok
Ryan Dercho
Senior Director of Corporate Affairsno dataVeri yokVeri yok

1.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: ZYME 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Kenneth Galbraith
Chairman of the Board2.8yrsUS$3.37m0.035%
$ 325.1k
Hollings Renton
Independent Director7.8yrsUS$264.00k0%
$ 0
Nancy Davidson
Independent Directorless than a yearUS$441.02k0%
$ 0
Neil Gallagher
Independent Directorless than a yearVeri yok0%
$ 0
Kelvin Neu
Independent Director4.7yrsUS$262.46k0%
$ 0
Susan Mahony
Lead Independent Director5.4yrsUS$261.83k0%
$ 0
Alessandra Cesano
Independent Directorless than a yearVeri yok0%
$ 0
Derek John Miller
Independent Director1.6yrsUS$555.15k0%
$ 0
Troy Cox
Independent Director5.4yrsUS$263.83k0.011%
$ 102.6k
Scott Platshon
Independent Directorless than a yearVeri yokVeri yok
Carlos Campoy
Independent Director1.4yrsUS$508.97k0%
$ 0
Troy Cox
no dataVeri yokVeri yok

1.6yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ZYME 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.